What's Happening?
Halia Therapeutics, a biopharmaceutical company based in Lehi, Utah, has announced the final results of its Phase 2 trial for ofirnoflast (HT-6184) in patients with lower-risk myelodysplastic syndrome
(LR-MDS). The results will be presented at the European Hematology Association (EHA) 2026 Hybrid Congress. The trial showed a 67% hematological improvement rate among patients, with significant transfusion independence and no serious treatment-related adverse events. Additionally, Halia has appointed Dr. Han Myint as Chief Medical Officer to lead the clinical development of ofirnoflast as it advances toward pivotal trials.
Why It's Important?
The development of ofirnoflast is significant as it addresses a critical unmet need in the treatment of lower-risk MDS, a condition characterized by ineffective blood cell production. The promising results from the Phase 2 trial suggest that ofirnoflast could offer a new therapeutic option for patients who are refractory to current treatments. The appointment of Dr. Myint, with his extensive experience in hematologic malignancies and drug development, is expected to strengthen Halia's efforts in advancing this treatment. This development could have a substantial impact on the biopharmaceutical industry, particularly in the field of hematology.
What's Next?
Halia Therapeutics plans to advance ofirnoflast into pivotal development stages, with further efficacy, safety, and biomarker data to be presented at the upcoming EHA Congress. The company is also focusing on expanding its pipeline to address other inflammasome-driven diseases. Dr. Myint's leadership is anticipated to guide the company through regulatory processes and potential commercialization, aiming to bring this novel therapy to market.
